touchIMMUNOLOGY caught up with William (Bill) Damsky (Yale School of Medicine, New Haven, CT, USA) to discuss the results from the BRAVE AA1 study (NCT03570749) investigating the use of baricitinib in the treatment of alopecia areata.
Questions
- What is the rationale for the use of JAK inhibitors in the treatment of alopecia areata? (0:12)
- Could you give us an overview of the BRAVE AA1 study and its efficacy and safety findings? (1:28)
- What is the clinical significance of these findings? (2:57)
- Which patients are likely to benefit most from baricitinib and in whom is it contraindicated? (3:35)
Disclosures: William Damsky is a consultant for Eli Lilly, Pfizer, and TWi Biotechnology; has received research funding from Pfizer and receives licensing fees from EMD, Millipore and Sigma.
Support: Interview and filming supported by Touch Medical Media.
